RxDoctor Payments Data

Benjamin Mason, MD

Ophthalmology · Waterloo, IANPI 1457301442

Payments from drug & device makers

What this record shows

This record is dominated by ownership interests: $2,403 of the $2,728 with a category attached, or 88.1%. US Retina LLC accounts for 88.1% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2022 at $1,106 and has fallen 93.8% since, to $69 in 2025.

$2,728in general payments, 2019–2025

Across 15 payments — averaging $181.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • US Retina LLC$2K
  • The Cameron-ehlen Group, Inc.$142
  • Alcon$97
  • AbbVie$51
  • Amgen$35

What the payments were for

  • Food & beverage$32512%
  • Ownership interest$2,40388%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
US Retina LLC5$2,403
The Cameron-ehlen Group, Inc.2$142
Alcon5$97
AbbVie2$51
Amgen1$35

How this compares

$2,728 in reported general payments places this provider in the 65th percentile of 172 ophthalmology providers in Iowa.

See all ophthalmology providers in Iowa

Medicare billing

Part B allowed, 2024
$721,147
Medicare patients
1,649
Services billed
6,368

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost360$135,802
RestasisCyclosporine75$47,662
RhopressaNetarsudil Mesylate125$42,438
Alphagan PBrimonidine Tartrate49$24,946
CombiganBrimonidine Tartrate/Timolol62$23,896
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol103$18,414
Latanoprost2,117$17,569
Prednisolone Acetate366$16,147
Brinzolamide78$12,324
Travoprost92$11,805
Timolol Maleate804$11,426
Cyclosporine29$11,379
Brimonidine Tartrate599$9,678
AzoptBrinzolamide20$8,826
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat557$8,623

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P, Combigan$51$232,306546 claims
AlconAzopt, Simbrinza$97$16,68361 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 172 ophthalmology providers in Iowa.

Other ophthalmology in Waterloo

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →